Law360 (April 26, 2018, 7:46 PM EDT) — A New Jersey federal jury rightly found that a Biogen MA Inc. patent covering its multiple sclerosis treatment Avonex was invalid, because while the patent covered a new process, the treatment was decades old, EMD Serono Inc. told the court Wednesday.
